<DOC>
	<DOC>NCT02409004</DOC>
	<brief_summary>This will be a single centre, Phase I, open-label, one cohort, one dose level, fixed-sequence, drug interaction study in healthy volunteers. The objective of this study is to determine the effects of rifampin on the pharmacokinetics of ataluren under fasting conditions.</brief_summary>
	<brief_title>Effects of Rifampin on the Pharmacokinetics of Ataluren</brief_title>
	<detailed_description />
	<mesh_term>Rifampin</mesh_term>
	<criteria>Healthy Male Nonsmoker ≥18 and ≤55 years of age Clinically significant laboratory, electrocardiogram, or vital sign abnormality at screening Positive urine drug screen at screening History of significant drug or alcohol abuse Recent use of medication other than topical products without significant systemic absorption Recent donation of plasma or blood or loss of blood</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Drug-drug interaction</keyword>
</DOC>